SLU-PP-332
pan-ERR agonist · ERRα/β/γ agonist · exercise mimetic
Mechanism of Action
SLU-PP-332 is a synthetic small-molecule pan-agonist of the estrogen-related receptors (ERRα, ERRβ, ERRγ), developed by Thomas Burris's group at Saint Louis University. ERRs are orphan nuclear receptors that drive transcription of mitochondrial biogenesis, fatty-acid oxidation, and oxidative-phosphorylation genes — the same programs activated by endurance exercise. In preclinical models the compound induces an exercise-mimetic gene-expression signature in skeletal muscle and reduces adiposity in diet-induced obese mice. It is a research-grade small molecule, not a peptide, with no completed human trials and no approved clinical indication.
Researched Benefits
Exercise-mimetic gene signature (preclinical)
In murine skeletal muscle, SLU-PP-332 induced transcriptional programs that overlap with endurance training — upregulating mitochondrial biogenesis, fatty-acid oxidation, and OXPHOS genes — without requiring physical activity.
- [Billon et al. 2023 (Nature Metabolism)]
Improved running endurance in mice
Treated mice ran longer distances on a treadmill versus vehicle controls, an effect attributed to enhanced muscle oxidative capacity rather than a stimulant action.
- [Billon et al. 2023]
Reduced adiposity in diet-induced obesity models
DIO mice on chronic SLU-PP-332 dosing showed lower fat mass and improved glucose tolerance compared to vehicle, consistent with elevated whole-body energy expenditure.
- [Billon et al. 2023]
Research Protocols
The following dosing ranges have appeared in published research protocols. Presented for informational purposes only — not a recommendation for human use.
Preclinical research reference
- Dosage
- 50 mg
- Frequency
- twice daily
- Timing
- morning and evening
- Cycle
- 4 weeks
Murine studies have used ~50 mg/kg intraperitoneal dosing twice daily. No validated human pharmacokinetic data, no oral bioavailability data in humans, and no approved formulation. Research use only.
Reported Side Effects
- No human safety data — no completed clinical trials
- ERR agonism affects multiple tissues (liver, muscle, brown adipose, heart, brain) — long-term effects on cardiac and hepatic gene programs in humans are unknown
- Anecdotal reports include transient fatigue and GI discomfort with experimental use
- Potential interaction with thyroid-hormone signaling pathways (preclinical observation)
Contraindications
- Pregnancy and lactation (no safety data)
- Active malignancy — ERRα is implicated in certain cancer biology
- Cardiac arrhythmias or structural heart disease (ERRs influence cardiac gene programs)
- Concurrent use with other mitochondrial-modulating compounds without research oversight
Stacking Partners
Peptides commonly paired with SLU-PP-332 in published research and protocol write-ups.
Vendor Pricing
Stacked earns a commission on purchases via these links. It does not influence our Trust Scores.
Top Videos
Curated from YouTube — refreshed weekly. Stacked doesn't host or endorse external content.
7:50Doctor Reveals 3 Mitochondrial Fixes That Boost Energy
This Is Not Covered - Dr. Ashley Froese
120.1K views · 7:50 · 6 months ago
9:14SLU-PP-332: My Results So Far (Update)
Tiger Fitness
46K views · 9:14 · 8 months ago
7:29What is SLU-PP-332
Regan Archibald
27.4K views · 7:29 · 4 months ago
8:25My experience using SLU-PP-332
Josh 'The Viking' Maley
18.5K views · 8:25 · 5 months ago
8:58Exercise in a Pill? The Truth About Sloop (SLU-PP-332)
Dr Nick Karr
13.7K views · 8:58 · 9 months ago
Research Papers
A synthetic ERR agonist alleviates metabolic syndrome
Billon C, Sitaula S, Banerjee S, et al. · Journal of Pharmacology and Experimental Therapeutics · 2023
PubMed 37105701 →Synthetic ERRα/β/γ agonist induces an ERR exercise-mimetic gene-expression signature in skeletal muscle and reduces obesity in mice
Billon C, Schoepke E, Avdagic A, et al. · Nature Metabolism · 2024
PubMed 39134750 →